The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Yeah Bella sounds good to me, as I said we are fully funded and more efficacy results will arrive before we need to concern ourselves with various options regarding more funding imo. Whether funding comes from DX options or licensing deal options or even Nasdaq options, the longer the positive data keeps emerging the stronger the position Avacta are in. We hired a very competent commercial expert in Dec, I have faith he will exceed expectations and deliver for the longterm.
The FY 2023 adjusted revenue for the Diagnostics Division is approximately £22 million and the revenue forecast for FY 2024 is approximately £24 million. The Diagnostics Division is expected to be EBITDA positive in 2H 2024 and cash generative in 2025.
In the placing RNS….. 😉
Deals will be likely, once phase 2 efficacy is published as it’s stated in the investment note we need partners for phase 3, however I do expect other third party deals to arrive not for AVA6000 as the data emerges over the next 2 years. That’s imo though.
Pointless discussion as we are fully funded and the DX business will be cash generating in 2025 so no reason to sell the business now. Build it up with full synergy and spin it off when things are fully integrated. Or keep it and see what happens. Deals will likely be done when more data emerges anyways.
Wtf you on about Touk do you not think the FDA will make a decision on AVA6000? Do you think the trial is actually fantasy and not real…. One way or another positive or negative a decision will be made on approval.
PS that white board on that video was explaining the general approval process for Avacta drug pipeline . Not individual drug candidates which will be analysed on a case by case basis, depending on the supporting evidence within the clinical trial.
Bella commercial 2026 according to the investment note. My point was the FDA will make a decision based on the emerging data sometime in the future. Could be phase 3 could be in the middle of phase 2 could even be approved by surrogate endpoint. What’s important is the FDA will make a decision though that’s inevitable. All we need to do is wait for the results and hopefully they will be positive.
“Ice, really, Its you that are so sure about everything. I am forever saying we don't know Jack.”
Windy why are you here???, my strategy pretty straightforward wait for FDA approval, what I can’t understand is if you don’t believe in my strategy, which let’s be honest the vast majority of LTH’s believe in my strategy, what’s the alternative, what do you want to achieve here on this BB? I really don’t understand why you bother if you don’t believe FDA approval will happen and it will be the catalyst for success, you are better off in other companies like CHAR. Also don’t worry about me, I bought way more at 43.5 and usually buy when it’s on sale my average is reducing all the time, however that’s not something that concerns me because, on FDA approval this will blast past ATH’s imo so anyone that bought at any time, will still be quids in. 👍😊
Are you on Avacta board meetings? You don’t have a clue what is going on??? You make huge hypothetical assumptions everyday, what contact has been made by BP we don’t have a clue what discussions have been done etc also Avacta obviously don’t care about the share price they were wanting institutional representation at all costs why is that? Maybe they wanted to protect any hostile takeover at the voting stage……. You really are an idiot sometimes, I still don’t think you are invested as well tbh.
Some hypothetical scenarios below.
Maybe Avacta are not for sale this raise was to protect any hostile takeover attempts.
Alternatively a price has already been agreed on condition of positive results in phase 2. That would explain why they don’t give a toss about current share price. If they have provisionally agreed a price on positive data, today’s price is irrelevant.
They are also building a platform of chemo drugs, I’m sure they probably could have rushed AVA6000 after cohort 4 however the fact they didn’t find an MTD and got valuable information will help the clinical process of other drug candidates AVA3996.
AVA6000 will get approved when it’s ready to get approved, you might be beholden to a timeline, I am happy to wait for the inevitable conclusion no matter how long it takes. (it will conclude and a decision will be made one way or another as data emerges) The prize on offer of approval of AVA6000 will be worth the wait in the long run, if you believe it will happen.
You all need to do some research on how much FDA oncology drugs are worth then re-evaluate the micro thinking, that further potential dilution will have any great impact on the investment case here. The Mkt cap here is only 175 million odd. Oncology drugs go into the billions not to mention full validation of platform. The science is exceptional, actually they say clearly proof of concept has been achieved. The sample size while small at the moment has been backed by 10+ biopsy data and nothing in the science says we won’t see efficacy in high fap dox sensitive tumours. So sheppy nothing in the science then just small sample size and yet to prove efficacy on paper how very boring 🥱. An FDA approval decision will happen inevitably. If positive that will be the catalyst for success here.
Sheppy simple question for you, with the science presented so far, why would the FDA not approve AVA6000? What in the evidence presented so far that is a stumbling block scientifically? I await an answer with bated breath. Also where the premium you are minted….. 😉
Windy number 1 that’s not how pharma takeovers work. Number 2 it’s what the board recommends and number 3 if a low takeover is accepted that’s the risk you take while investing, nothing I can do to change that so why worry in the meantime.
“Jesus I am in a comedy club. here are a few more for you Ice. "Dont worry about funding", "Shareholder Value", "No Placing" "Raise unlikely at under £1" "Start of the value curve" "Start of commercialisation" "Lots want it" "Prefer non dilutive methods" "We dont know how to use a calulator but please take us seriously" "I have a lot riding on avacta as I have a lot of options (Plus my small 400k salary)"
What’s the above got to do with making cash on FDA approval of AVA6000. Making changes this late in the game won’t help anything.
Who says they are mistakes, short term share price fluctuations has no impact on the company being successful and making good longterm strategic decisions for the overall benefit of the investors. We will ultimately see how this plays out I will be here not sure you will be. 😉😝
Haha rose tinted glasses you require spec savers you are so short sighted it is unbelievable. At the end of the day all that matters is funding and FDA approval. The science strongly suggests we will get FDA approval. On FDA approval even if we did another 50% Dilution the company would still be valued in the Billions based on validation of drug and platform. Approved Oncology drugs are worth some serious cash who would have thought. Not rose tinted glasses just good old logical conclusions if the trial is successful which the data suggests it will be.